Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity

Journal of Clinical Investigation

Volumn 98, Issue 3, 1996, Pages 610-615

  Wei, Xiaoxiong ^a   McLeod, Howard L ^b   McMurrough, Julieann ^b   Gonzalez, Frank J ^a   Fernandez Salguero, Pedro ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

5 FU toxicity; DPD deficiency; exon skipping; population genotyping

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL;

ALLELE; ARTICLE; CANCER PATIENT; CATALYSIS; ENZYME ACTIVITY; ENZYME DEFICIENCY; EXON; GENE DELETION; GENE MUTATION; GENETIC SCREENING; GENOTYPE; HUMAN; HUMAN CELL; MOLECULAR CLONING; PEDIGREE; POINT MUTATION; PRIORITY JOURNAL; PYRIMIDINE METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0029973215     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118830     Document Type: Article

References (27)

1. Gonzalez, F.J., and P. Fernandez-Salguero. 1995. Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency. Trends. Pharmacol. Sci. 16:325-327.
2. Chabner, B.A., and C.E. Myers. 1985. Clinical pharmacology of cancer chemotherapy. In Cancer, Principles and Practice of Oncology. V.T. DeVita, S. Hellman, and S.A. Rosenberg, editors. J.B. Lippincott Co., Philadelphia. 287-328.
3. Woodcock, T.M., D.S. Martin, L.E.M. Damin, N.E. Kemeny, and C.W. Young. 1980. Combination clinical trials with thymine and fluorouracil: a phase I and clinical pharmacologic evaluation. Cancer. (Philadelphia). 45:1135-1143.
4. Berger, R., S.A. Stoker-de Vries, S.K. Wadman, M. Duran, R.A. Beemer, P.K. deBree, J.J. Weits-Binnerts, T.J. Renders, and J.K. van der Woude. 1984. Dihydropyrimidine dehydrogenase deficiency leading to thymine-uraciluria. An inborn error of pyrimidine metabolism. Clin. Chim. Acta. 141:227-234.
5. Bakkeren, J.A.J.M., R.A. De Abeu, R.C.A. Sengers, F.J.M. Gabreels, J.M. Maas, and W.O. Renier. 1984. Elevated urine, blood and cerebrospinal fluid levels of uracil and thymine in a child with dihydropyrimidine dehydrogenase deficiency. Clin. Chim. Acta. 140:247-256.
6. Wadman, S.K., R. Berger, M. Duran, P.K. deBree, S.A. Stoker-de Vries, F.A. Beemer, J.J. Weits-Binnerts, T.J. Penders, and J.K. van der Woude. 1985. Dihydropyrimidine dehydrogenase deficiency leading to thymine-uraciluria. An inborn error of pyrimidine metabolism. J. Inherit. Metab. Dis. 8:113-114.
7. Brocksted, M., C. Jakobs, L.M.E. Smit, A.H. vanGennip, and R. Berger. 1990. A new case of dihydropyrimidine dehydrogenase deficiency. J. Inherit. Metab. Dis. 8:115-116.
8. Tuchman, M., J.S. Stoeckeler, D.T. Kiang, R.F. O'Dea, and M.L. Ramnaraine. 1985. Familial pyrimidine and pyrimidinemia associated with severe fluorouracil toxicity. N. Engl. J. Med. 313:245-249.
9. Diasio, R.B., T.L. Beavers, and J.T. Carpenter. 1988. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J. Clin. Invest. 81:47-51.
10. Harris, B.E., J.T. Carpenter, and R.B. Diasio. 1991. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency: a potentially more common pharmacogenetic syndrome. Cancer (Philadelphia). 68: 499-501.
11. Houyau, P., C. Gay, E. Chatelut, P. Canal, H. Roche, and G. Milano. 1993. Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency [letter]. J. Natl. Cancer Inst. 85:1602-1603.
12. Meinsma, R., P. Fernandez-Salguero, A.B. van Kuilenburg, A.H. Van Gennip, and F.J. Gonzalez. 1995. Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uruciluria. DNA Cell. Biol. 14:1-6.
13. Milano, G., and M.-Ch. Etienne. 1994. Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy. Pharmacogenetics. 4:301-306.
14. Milano, G., and M.-Ch. Etienne. 1994. Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil (review). Anticancer Res. 14:2295-2297.
15. Yokota, H., P. Fernandez-Salguero, H. Furuya, K. Lin, O.W. McBride, B. Podschun, K.D. Schnackerz, and F.J. Gonzalez. 1994. cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria. J. Biol. Chem. 269:23192-23196.
16. McMurrough, J., and H.L. McLeod. 1996. Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br. J. Clin. Pharmacol. 41:425-427.
17. Chomczynski, P., and N. Sacchi. 1987. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
18. Fernandez-Salguero, P., S.M.G. Hoffman, S. Cholerton, H. Mohrenweiser, H. Raunio, A. Rautio, O. Pelkonen, J.-d. Huang, W.E. Evans, J.R. Idle, and F.J. Gonzalez. 1995. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am. J. Hum. Genet. 57:651-660.
19. Marvit, J., A.G. DiLella, K. Brayton, K.J.H. Robson, and S.L.C. Woo. 1987. GT to AT transition at a splice donor site causes skipping of the preceding exon in phenylketonuria. Nucleic Acids Res. 15:5613-5628.
20. Cole, W.G., A.A. Chiodo, S.R. Lamande, R. Janeczko, F. Ramirez, H.H.M. Dahl, D. Chan, and J.F. Bateman. 1990. A base substitution at a splice site in the COL3A1 gene causes exon skipping and generates abnormal type III procollagen in a patient with Ehlers-Danlos syndrome type IV. J. Biol. Chem. 265:17070-17077.
21. Steingrimsdottir, H., G. Rowley, G. Dorado, J. Cole, and A.R. Lehmann. 1992. Mutations which alter splicing in the human hypoxanthine-guanine phosphoribosyltransferase gene. Nucleic Acids Res. 6:1201-1208.
22. Robberson, B.L., G.J. Cote, and S.M. Berget. 1990. Exon definition may facilitate splice site selection in RNAs with multiple exons. Mol. Cell. Biol. 10: 84-94.
23. Berget, S.M. 1996. Exon recognition in vertebrate splicing. J. Biol. Chem. 270:2411-2414.
24. Fernandez-Salguero, P., F.J. Gonzalez, M.-Ch. Etienne, G. Milano, and S. Kimura. 1995. Correlation between catalytic activity and protein content for the polymorphically expressed dihydropyrimidine dehydroyenase in human lymphocytes. Biochem. Pharmacol. 50:1015-1020.
25. Lu, Z., R. Zhang, and R.B. Diasio. 1993. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res. 53:5433-5438.
26. Lu, Z., R. Zhang, and R.B. Diasio. 1995. Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. Clin. Pharmacol. Ther. 58:512-522.
27. Fleming, R.A., G. Milano, A. Thyss, M.-Ch. Etienne, N. Renee, M. Schneider, and F. Demard. 1992. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res. 52:2899-2902.